Abstract:<span class="paragraphSection">BackgroundPalliative care units (PCU) have shown an improvement in the quality of life of patients with cancer by reducing overtreatments at the end of life and increasing symptomatic care at home, avoiding unnecessary emergency room visits and decreasing the number of hospital admissions.MethodsA retrospective observational study was conducted, selecting all patients with a first consultation in the Medical Oncology Unit of the Puerta de Hierro University Hospital (HUPdH) between 2014 and 2015 and died before December 31st 2017. Assessment by PCU, number of hospital admissions and re-admissions and most frequent symptoms for admission in the last 6 months of life were reviewed. The main objective was to know if there were differences between those who were valued by PCU or not.ResultsA total of 662 patients were selected. From them, 86 (13%) patients had never been admitted at HUPdH, 312 (47%) had been admitted once, 169 (26%) twice and 95 (14%) three or more times. Before death, 474 (72%) had been valued by PCU and 302 did not received PCU visit before the second hospital admission episode. The three most frequent causes of admission were deterioration of the general condition, infections and uncontrollable pain. In those with an assessment by PCU before the second admission process, there was a significant decrease in the number of readmissions (25% versus 68%). Moreover, in these patients, there was a statistically significant decrease in the number of re-admissions because of the three main causes of admission but also in others, such as dyspnea, neurological worsening, bleeding and nauseas and vomiting. (Table). Table:1606PPCU: Percentage of patients re-admitted with an assessment by palliative care unit by the time of re-admission; Non PCU: Percentage of patients re-admitted without assessment by palliative care units before re-admissionSymptomPCUNon PCURisk RatioDeterioration of the general condition9%21%RR 0.41, 95% CI 0.27-061, p < 0.0001Dyspnea3%13%RR 0.24, 95% CI 0.12-0.45, p < 0.0001Neurological worsening2%8%RR 0.25, 95% CI 0.11-0.56, p < 0.0001Infections5%24%RR 0.20, 95% CI 0.12-0.32, p < 0.0001Uncontrollable pain5%15%RR 0.35, 95% CI 0.21-0.59, p < 0.001Nauseas and vomiting2%7%RR 0.32, 95% CI 0.14-0.71, p < 0.003Bleeding2%7%RR 0.34, 95% CI 0.15-0.75%, p < 0.005ConclusionsIn our cohort, in patients with an assessment by PCU before the second admission episode, was observed a decrease in number and severity of re-admissions. An optimization of the symptomatic treatment at home implies a decrease in hospital-acquired or nosocomial complications which leads to a reduction in costs and above all, an improvement in the quality life both of patients and their families.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.</span>

Early palliative care program in idiopathic pulmonary fibrosis patients favors at-home and hospice deaths, reduces unplanned medical visits, and prolongs survival: A pilot study

Referral to pulmonary rehabilitation and palliative care services in people with idiopathic pulmonary fibrosis in England, 2010–2019

Partnership delivery of symptom management at a UK ILD centre

Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature

Advance Care Planning: A Retrospective Audit in a National Referral Center for Interstitial Lung Diseases

Impact of COVID-19 on emergency department visits among palliative home care recipients: a retrospective population-based cohort study in the Piedmont region, Italy

Insights from an Italian Prospective Cohort Study

Early palliative care in advanced cancer: Is it really effective?

Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue

Study on the efficacy of early treatment with pirfenidone on the lung function of patients with idiopathic pulmonary fibrosis

Comparison of the Life-Sustaining Treatment, Cardiopulmonary Resuscitation, and Palliative Care Implementation Rates between Homebound Patients with Malignant and Nonmalignant Disease Who Died in an Acute Hospital Setting: A Single-Center Retrospective Study

When should palliative care be introduced for people with progressive fibrotic interstitial lung disease? A meta-ethnography of the experiences of people with end-stage interstitial lung disease and their family carers

Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry

Differences in Healthcare and Palliative Care Utilization at the End of Life: a Comparison Study Between Lung Cancer, COPD, and IPF

Lesson Learned From Hospital Palliative Care Service in a Cancer Research Center in Italy: Results of 5 Years of Experience

End-of-life of patients with idiopathic pulmonary fibrosis treated with antifibrotic therapy

IPF and lung cancer. Retrospective analysis of antifibrotic drugs and thoracic surgery.

An App Platform-Facilitated Collaborative Palliative Care Intervention for Outpatients With Interstitial Lung Disease: A Pilot Randomized Trial

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review

Palliative sedation and time to death in home palliative care: retrospective analysis